Document Type : Original Article


1 Basrah Health Directorate, Basrah, Iraq

2 Department of Dermatology, College of Medicine, University of Basrah, Basrah, Iraq

3 Department of Biochemistry, College of Medicine, University of Basrah, Basrah, Iraq

4 Specialized Endocrine and Diabetes Center, Almawani Hospital,Basrah, Iraq

5 Alzahraa Medical College, University of Basrah, Basrah, Iraq


Background: Psoriasis is a chronic, recurrent, inflammatory, and proliferative disease. Previous studies have demonstrated that patients with psoriasis may have an increased risk of developing
coronary artery disease. High serum lipid levels have been suggested in the pathogenesis of this phenomenon. Accumulating evidence suggests that apolipoprotein B is superior to other lipid
parameters in predicting atherosclerotic cardiovascular disease. This study aimed to examine the differences in the lipid profile and apolipoprotein A-I and apolipoprotein B levels between psoriatic patients and healthy subjects.
Methods: This was a case-control, cross-sectional study. A total of 93 psoriatic patients and 113 healthy individuals were enrolled. This study was conducted at the outpatient department of dermatology in Alsader Teaching Hospital, Basra, Iraq. The serum level of total cholesterol (TC), triglyceride (TG), very lowdensity lipoprotein cholesterol (VLDL-C), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein A-I and apolipoprotein B were measured.
Results: The psoriatic patients had significantly higher levels of TC, TG, VLDL-C, LDL-C, and apolipoprotein B compared with the control group.
Conclusion: Lipid profile values were significantly higher among patients with psoriasis than normal controls. Early screening and treatment of hyperlipidemia in these patients are advisable to
prevent atherosclerosis and its complications. Apolipoprotein B may serve as a marker for dyslipidemia and CVD in patients with psoriasis.